Search results for "Virus"

showing 10 items of 5024 documents

Efficiency of COVID-19 Testing Centers in Iran: A Data Envelopment Analysis Approach

2022

AbstractObjective:The purpose of this study is to investigate the efficiency of the Iranian Red Crescent Society (IRCS) in managing their nonmonetary resources involved in coronavirus disease 2019 (COVID-19) response.Methods:For this purpose, the data envelopment analysis approach was used to measure the efficiency, considering the number of personnel and vehicles and screened passengers as the input and output parameters, respectively. It was examined the efficiency of 10 IRCS’s branches given 17 d of screening operation. For the analysis, the DEA SolverPro software 15a version was used.Results:The results show that only 1 branch had been fully efficient in using the resources, while 5 bra…

resources management2019-20 coronavirus outbreakMeasure (data warehouse)Coronavirus disease 2019 (COVID-19)Operations researchComputer scienceSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Public Health Environmental and Occupational HealthCOVID-19BurnoutRed CrescentIndirect costspandemic responseefficiencyData envelopment analysisIranian Red Crescent Societydata envelopment analysisOriginal Research
researchProduct

RSV disease in infants and young children: Can we see a brighter future?

2022

Respiratory syncytial virus (RSV) is a highly contagious seasonal virus and the leading cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in children. RSV-related LRTI cause approximately 3 million hospitalizations and 120,000 deaths annually among children <5 years of age. The majority of the burden of RSV occurs in previously healthy infants. Only a monoclonal antibody (mAb) has been approved against RSV infections in a restricted group, leaving an urgent unmet need for a large number of children potentially benefiting from preventive measures. Approaches under development include maternal vaccines to protect newborns, extended half-life monoclon…

respiratory syncytial virusImmunologyRSV vaccinesRespiratory Syncytial Virus InfectionsCommunicable DiseasesRSV preventionRSV all infantsImmunology and AllergyHumansChildmonoclonal antibodieRespiratory Tract InfectionsPharmacologyRSV all infantInfant NewbornRSVInfantAntibodies MonoclonalRSV paediatric burdenHospitalizationLRTIRSV epidemiologyChild PreschoolRespiratory Syncytial Virus HumanBronchiolitismonoclonal antibodiesLRTI; RSV; RSV all infants; RSV epidemiology; RSV paediatric burden; RSV prevention; RSV vaccines; monoclonal antibodies; respiratory syncytial virusRSV prevention: RSV vaccines.Human vaccinesimmunotherapeutics
researchProduct

The need for a special restructuring procedure for insolvent entrepreneurs due to SARS-CoV-2

2020

This text refers to the need for simple restructuring proceedings for entrepreneurs due to the crisis caused by the coronavirus epidemic. Some countries may be more deeply affected by the crisis, others may be more resilient to economic shocks. The comments are abstract. They do not refer to any particular legal system. Their purpose is to provoke a general discussion on the need to introduce into the legislation special rules regarding business insolvency as a result of the SARS-CoV-2 pandemic. The main assumption is as follows. The main purpose of insolvency law is to maximize creditors’ satisfaction. Meanwhile, in the event of a common, structural crisis, a more important value may be ma…

restructuringbankruptcycoronavirus financial crisisСоциально-Политические Науки = Socialʹno-Političeskie Nauki
researchProduct

Heterogeneity and dynamics of evolution of G1 human rotavirus in Palermo: alternate circulation of different lineages and sub-lineages

2006

A rotavirus sample collection from 19 consecutive years was used to investigate the heterogeneity and the dynamics of evolution of G1 rotavirus strains in a geographically defined population. Phylogenetic analysis of the VP7 gene sequences of G1P[8] human rotavirus strains showed the circulation of a heterogeneous population comprising three lineages and seven sublineages. Increases in the circulation of G1 rotaviruses were apparently associated with the introduction of novel G1 strains that exhibited multiple amino acid changes in antigenic regions involved in rotavirus neutralization compared to the strains circulating in the previous years. The emergence and/or introduction of G1 antigen…

rotavirus G1
researchProduct

Antígenos histo-sanguíneos e infección por rotavirus

2019

La infección por rotavirus es la principal causa de gastroenteritis aguda en niños menores de 5 años en todo el mundo. Su incidencia es similar en países desarrollados y en vías de desarrollo, aunque la mayor mortalidad ocurre en estos últimos. Las vacunas frente a rotavirus han demostrado una gran efectividad en los países industrializados, pero su protección es menor en los países del África subsahariana y Asia. Se ha descrito que los antígenos histo-sanguíneos, presentes en la membrana de los enterocitos, actúan como ligandos para distintos genotipos de rotavirus. Esto podría explicar las diferencias que se observan en su distribución geográfica y la distinta eficacia vacunal de unas áre…

rotavirusUNESCO::CIENCIAS MÉDICASantígenos histo-sanguíneos:CIENCIAS MÉDICAS [UNESCO]
researchProduct

Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b vaccine; Infanrix™ hexa: T…

2014

Infant vaccination using 2-dose priming at 3 and 5 mo of age with a booster at 11–12 mo of age was pioneered in Italy. The 3-5-11 schedule is now used in a growing number of European countries. Infanrix™ hexa (DTPa-HBV-IPV/Hib, GlaxoSmithKline Vaccines) was first licensed for use in 2000 and has been the only pediatric hexavalent vaccine available since 2005. We reviewed available clinical trial data describing the immunogenicity of DTPa-HBV-IPV/Hib when administered at 3, 5, and 11 mo of age, and conducted an analysis of safety using global and Italian post-marketing surveillance data. In Italy, DTPa-HBV-IPV/Hib has a demonstrated safety record extending over a decade of use, it has been a…

safetybooster vaccination; combination vaccines; hexavalent vaccine; immunogenicity; Italy; primary vaccination; safety; Clinical Trials as Topic; Diphtheria-Tetanus-Pertussis Vaccine; Haemophilus Vaccines; Hepatitis B Vaccines; Humans; Italy; Poliovirus Vaccine Inactivated; Product Surveillance Postmarketing; Vaccination; Vaccines Combined; Medicine (all)Settore MED/42 - Igiene Generale e ApplicataImmunologySocio-culturaleReviewimmunogenicitySettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeprimary vaccinationProduct Surveillance PostmarketingmedicineImmunology and AllergyHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesPharmacologycombination vaccinesbooster vaccination; combination vaccines; hexavalent vaccine; immunogenicity; Italy; primary vaccination; safety; Medicine (all)Clinical Trials as TopicVaccinescombination vaccineTetanusbusiness.industryCombinedImmunogenicityPoliovirusDiphtheriaMedicine (all)VaccinationInactivatedHepatitis Bmedicine.diseaseVirologyProduct SurveillancePostmarketingClinical trialVaccinationPoliovirus Vaccinebooster vaccinationPoliovirus Vaccine InactivatedInfanrix hexaItalyhexavalent vaccine; primary vaccination; booster vaccination; Italy; combination vaccines; immunogenicity; safetybusinesshexavalent vaccine
researchProduct

SARS-COV-2 PANDEMIC IN THE MEDITERRANEAN AREA: EPIDEMIOLOGY AND PERSPECTIVES

2020

In December 2019, a disease caused by a novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was identified in Wuhan, Hubei Province, China. In March 2020, the World Health Organization declared the pandemic due to SARS-CoV-2. At the end of May 2020, SARS-CoV-2 confirmed cases and deaths due to novel Coronavirus disease (COVID-19) were about 6.5 million and 380,000, worldwide. In this commentary the authors argue on the impact of SARS-CoV-2 pandemic in different epidemiological settings within the Mediterranean area, discussing any possible association with higher or lower virus spread according to climatic factors, pollutants, characteristics of general population, and organi…

sars-cov-2mediterranean arealcsh:R5-920covid-19virusespandemicpublic healthvirus diseasesepidemiologyskin and connective tissue diseaseslcsh:Medicine (General)Euromediterranean Biomedical Journal
researchProduct

Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19?

2021

severe asthma2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Severe asthmaImmunologyComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioCOVID-19 severe asthma COPDNOHumans; SARS-CoV-2; Asthma; COVID-19Internal medicineCorrespondencemedicineCOPDImmunology and AllergyHumansAsthmaCOVIDbusiness.industrySARS-CoV-2COVID-19asthmamedicine.diseaseItalybusiness
researchProduct

COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments

2020

To the Editor Since the end of February 2020 Italy, first non- Asian Country, has reported an ever increasing number of COronaVIrus Disease 19 (COVID-19) patients, which has reached over 200,000 confirmed Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) infected subjects and resulted in more than 34000 deaths (data updated to June 19th, 20201).Patients with asthma are potentially more severely affected by by SARS-CoV-2 infection 2 and it is well established that respiratory viral infections are associated with severe adverse outcomes in patients with asthma, including increased risk of asthma exacerbation episodes 3. Nonetheless, according to the epidemiological studies publishe…

severe asthmamedicine.medical_specialty2019-20 coronavirus outbreakCOVID-19 Severe Asthma Network in Italy inflammationCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Severe asthmaPopulationImmunologyMEDLINEOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioNOInternal medicineDiabetes mellitusSeverity of illnessmedicineImmunology and AllergyRisk factorLetters to the EditoreducationLetter to the EditorAsthmaeducation.field_of_studybusiness.industryIncidence (epidemiology)Mortality rateCOVID-19medicine.diseaseComorbiditySevere Asthma Network in ItalyinflammationCohortbusinessMepolizumabmedicine.drug
researchProduct

Influence of sexual sensation seeking, sexual compulsivity and sexual pleasure in condom use among Spanish youth: implications for HIV interventions

2016

Spain is one of the countries with the highest incidence of HIV within the European Union. Multiple and complex factors influence HIV infection in young people. This study aims to determine the influence of sexual sensation seeking, sexual compulsivity and perceived sexual pleasure variables in condom use. A total of 424 heterosexual youth were evaluated (M age = 20.62; SD = 2.62) distributed into a risk group (60.7%) and a no-risk group (39.3%). Sexual Sensation Seeking Scale, AIDS Prevention Questionnaire, Sexual Compulsivity Scale, and Sexual Pleasure Perceived Scale were administered. Results indicate statistically significant differences in sexual sensation seeking (p=.001), failure to…

sexual compulsivityPsychological interventionHuman immunodeficiency virus (HIV)condom usemedicine.disease_causelaw.inventionDevelopmental psychologySexual compulsivitySexual pleasureCondomAcquired immunodeficiency syndrome (AIDS)lawmedicineSensation seekingsexual sensation seekingSidayouthbiologyHIV interventionsSexualitat (Psicologia)biology.organism_classificationmedicine.diseasesexual pleasurePsychologyClinical psychology
researchProduct